Voyager Therapeutics shares surge 25.06% intraday after beating Q4 2025 earnings estimates and reporting strong cash reserves.

Voyager Therapeutics surged 25.06% intraday, driven by a Q4 2025 earnings report that beat expectations with higher-than-anticipated losses and revenue, strong cash reserves projected to support operations through 2028, and positive analyst ratings from major institutions like Citigroup and H.C. Wainwright, who set a target price as high as $25, reflecting confidence in its gene therapy pipeline.